Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Revance Therapeutics (RVNC) Misses Q1 EPS by 7c; Offers FY23 Revenue Guidance
May 9, 2023 4:58 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.74), $0.07 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $49.3 million versus the consensus estimate of $45.73 million.
GUIDANCE:
Revance Therapeutics sees FY2023 revenue of $460-480 million.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
... More